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Group 1 innate lymphoid cells (ILCs) comprise the natural killer (NK) cells and ILC1s 
that reside within peripheral tissues. Several different ILC1 subsets have recently been 
characterized; however, no unique markers have been identified that uniquely define 
these subsets. Whether ILC1s and NK cells are in fact distinct lineages, or alternately 
exhibit transitional molecular programs that allow them to adapt to different tissue niches 
remains an open question. NK cells are the prototypic member of the Group 1 ILCs and 
have been historically assigned the functions of what now appears to be a multi-subset 
family that are distributed throughout the body. This raises the question of whether each 
of these populations mediate distinct functions during infection and tumor immunosur-
veillance. Here, we review the diversity of the Group 1 ILC subsets in their transcriptional 
regulation, localization, mobility, and receptor expression, and highlight the challenges in 
unraveling the individual functions of these different populations of cells.
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iNTRODUCTiON
Innate lymphoid cells (ILCs) are members of an expanding family of immune cells that provide the 
first line of defense against invading pathogens and they also contribute to tissue repair (1). Unlike 
T and B lymphocytes, ILCs develop independent of the recombinant activating gene (RAG). They 
have been classified into three main groups (groups 1–3) based on their cytokine and transcription 
factor expression that aligns them with the subsets used to categorize different CD4+ T helper (Th) 
cell populations (2). The ILC1 family, such as Th1 cells, is composed of the T-bet-expressing cells 
that secrete interferon (IFN)-γ. Group 2 ILCs (ILC2s), initially described as “natural helper cells” 
(3), or nuocytes (4), express GATA-3 similar to Th2 CD4+ T cells, while ILC3s produce IL-17 and/or 
IL-22 and express the transcription factor RORγt (5). This latter subset is proposed to be equivalent 
to Th17 and Th22 cells.
Innate lymphoid cells have been the focus of extensive investigation during the last 5 years, in 
part due to their potential impact on human health and disease. Several studies have uncovered 
significant heterogeneity and plasticity within the ILC subsets, a feature which highlights that the 
field may have overlooked delineating the individual contributions of different ILC subsets and 
identifying their contributions to immunity. This is especially important in the Group 1 ILCs that 
were originally thought to represent a single homogeneous population composed of natural killer 
(NK) cells alone. It has now been found that this group is heterogeneous and includes a second 
subset of T-bet-dependent IFN-γ-producing innate cells that localize principally in tissues (6). 
Given this diversity within the group 1 ILCs we will refer to the respective subsets as NK cells and 
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ILC1s. The finding that two IFN-γ-producing subsets exist also 
raises the possibility that previous analyses of NK cells may have 
overlooked the contributions of ILC1s as they express similar 
surface markers, including NKp46, CD122, and NK1.1, to NK 
cells. However, it is now recognized that NK cells and ILC1s 
are likely to have quite distinct roles in protective immunity as 
they differ in multiple aspects, including their transcriptional 
regulation, localization, mobility, and receptor expression. The 
challenge in teasing apart the individual functions of these dif-
ferent populations of cells relies largely on the identification of 
unique markers to characterize each of the populations. In this 
review, we provide an overview of the different Group 1 ILC 
populations and highlight the current understanding of their 
roles in immune protection.
HeTeROGeNeiTY AND PLASTiCiTY 
OF THe GROUP 1 iLCs
Group 1 ILCs were initially thought to include only the prototypic 
member, the NK cell. Even early on though, heterogeneity had 
already been described among NK cells found in different tissues, 
such as the liver, the thymus, and the uterus. These NK cells differ-
entially expressed a number of surface molecules, suggesting that 
much greater diversity existed (7). Classically, NK cells have been 
defined as CD3−NK1.1+ with NKp46 expression being identified 
somewhat later as a more specific marker for mature NK cell cells 
that are found in secondary lymphoid tissues, such as lymph nodes 
and the spleen (8). A further subset of ILC1s, initially thought to 
be NK cells, was found in the liver and expressed the molecule 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
(9). More recently, it has been shown that the intrahepatic ILCs 
comprise a distinct lineage of ILC1s which develops separately 
from NK cells (10). ILC1s have also been found in the thymus and 
express high levels of the IL-7 receptor α (IL-7Rα, CD127) and 
Gata-3 (11). A further distinction has been elucidated between 
NK cells and ILC1 as the latter are generally localized within 
tissues. This has led to their designation as “tissue-resident” cells. 
This contrasts with the majority of NK cells that at steady-state 
circulate continuously patrolling for infected or malignant cells, 
while ILC1 rarely recirculate and appear to be generated by 
progenitor cells in the tissues or self-renew locally (6, 12). How 
the behavior of these two subsets of cells might be altered during 
inflammation is not yet clear. It is possible that in response to 
infection bone marrow-derived precursors become key contribu-
tors to the pool of tissue-resident ILC1s to meet the significantly 
increased demands of responding to a pathogen infection. Some 
evidence for such a model is provided by the adoptive transfer 
of bone marrow ILC progenitors into sublethally irradiated mice 
that were then able to generate liver and intestinal ILC1s (13, 14).
Conventional NK Cells
Natural killer cells represent 5–15% of circulating lymphocytes 
in humans and 2–5% in mice. It is well established that tumor 
growth is in part influenced by the activity of the immune sys-
tem. However, it has only recently been appreciated that tumor 
cell avoidance of immune detection also contributes to cancer 
development in humans. NK cells were identified in the early 
1970s due to their ability to spontaneously kill leukemia cells and 
they have now been strongly implicated as key effectors in cancer 
immunosurveillance, transplantation rejection, and early viral 
immunity (15).
The cytokine IL-15 is essential for most facets of NK cell biol-
ogy. It binds to IL-15Rβ/γc heterodimers on the surface of NK 
cells to drive their survival and proliferation. It also primes NK 
cell activation resulting in the production of pro-inflammatory 
cytokines and lytic granules. IL-15 binding results in activation 
of the JAK1/3 and STAT5 signaling pathways and this induces 
STAT5-target genes, such as the pro-survival gene Myeloid cell 
leukemia 1 (Mcl1) and the negative regulator of IL-15 signaling 
(16), cytokine-inducible SH2-containing protein encoded by 
Cish, which are essential for NK cell survival and homeostasis 
(17). The NK cells also express multiple activating and inhibitory 
receptors of the NKG2 and Ly49 (KIR in humans) family (18). The 
activation of the NK cells relies on the dynamic balance between 
activating and inhibitory pathways allowing the cells to rapidly 
sense changes in the environment. NK cells can kill infected or 
transformed cells through cytolytic mechanisms (granzymes or 
perforin) or engagement of death receptors.
iLC1s
ILC1s are found at steady state in virtually all tissues, but are 
enriched in the liver, uterus, skin, salivary glands, and the gut 
(19). In contrast to NK cells that express integrin α2 (CD49b), 
ILC1s express high levels of integrin α1 (CD49a) but lack integrin 
α2 and the T-box transcription factor eomesodermin (Eomes). 
Conventionally, Eomes expression has been thought to be 
restricted to NK cells alone and not expressed by ILC1s. However, 
this does not appear to be a universal rule as ILC1s in some tissues 
can also express Eomes highlighting that the use of transcription 
factor expression to demarcate subsets is not necessarily defini-
tive in all settings (Table  1; Figure  1). Similarly, while CD49a 
expression is restricted to ILC1 at steady state, following activa-
tion, NK cells can also express this marker (20). This incomplete 
clarity in defining the subsets highlights their complexity and the 
requirement to dig deeper into understanding the distinct roles 
of ILC1s and NK cells in vivo.
Liver ILC1s
Natural killer cells that differed from conventional NK cells 
were identified in the liver by the Smyth group who described 
a unique subset of NK1.1+ cells that expressed TRAIL (9). 
Initially, they were considered to be immature NK cells as they 
were enriched for CD27+CD11b− cells that lacked expression 
of most of the Ly49 molecules and CD49b (9). It is now clear 
that this population is a distinct ILC1 lineage that in contrast 
to NK cells, which does not require the transcription factor 
nuclear factor interleukin 3 (Nfil3) for development (10) and 
is tissue-resident being located almost solely in the liver at 
steady state (12) (Figure  1B). Interestingly, liver ILC1s share 
with other tissue-resident lymphocytes the dependency on 
the transcription factor Hobit, while ILC1s in other tissues 
do not (39). Transcriptomic analysis revealed that liver ILC1 
gene expression was quite distinct from NK cells (10). ILC1s 
display a unique pattern of chemokine receptors and adhesion 
TABLe 1 | Phenotype of NK cells and tissue-specific iLC1.
NK1.1 NKp46 CD49a CD49b CXCR6 CD127 TRAiL CD160 CD226 Ly49e CD11b KLRG1 CD62L eOMeS
NK cells + + – + – – – – + – + + + +
Liver ILC1 + + + – + ± + + ++ + – – – –
Thymic ILC1 + + n.d. + n.d. + n.d. n.d. n.d. n.d. – – n.d. +
IEILC1 + + + – + + + + + – – – – –
Salivary ILC1 + + + + + – + + n.d. n.d. – – – +
±, heterogeneous expression; n.d., not determined.
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molecules distinct from NK cells. These are likely to be important 
in maintaining their resident positioning in tissues and include 
the receptors CXCR6, CXCR3, CD103, CD49a, CD69, and CD39 
(10, 12, 33). By contrast, NK cells express CX3CR1, CD62L, 
S1PR1, and S1PR5 that are not found in the ILC1. Liver ILC1s 
also express their own pattern of cytokine receptors (IL-7R, 
IL-17RD, IL-21R, and TGF-βR) together with a set of regulatory 
molecules, such as CD200R, PD1-L, ICOSL, and Lag3 (10, 33).
It is now clear that intrahepatic ILC1s are resident cells; 
however, how the stability of this population maintained is not 
clear. Several studies have been undertaken to understand this 
feature of ILCs but the outcomes have not been consistent (12, 
40). One possibility for these discrepancies could be that mouse 
strains of different backgrounds that have been used as recipients 
of adoptively transferred ILC1s may impact the development and 
expansion of these cells. For example, liver ILC1s transferred into 
sublethally irradiated C57BL/6 mice maintained their original 
phenotype (12), while ILC1s transferred into immunodeficient 
Rag2−/−γc−/− mice differentiated into NK cells that then expressed 
Eomes and lost surface TRAIL expression (40).
Intrahepatic ILC1s have also been identified in man (41). 
Interestingly, these cells share many phenotypic traits with 
mouse liver ILC1s, including the expression of CD49a, NKp46, 
DNAM-1, and T-bet, but lack Eomes (41). They appear to also 
share similar functional capacity as they produce high levels of 
IFN-γ, TNF-α, and GM-CSF, a poor degranulation response and 
low levels of cytotoxic effector molecules. Despite the conserva-
tion of characteristics between man and mouse, the actual role 
of the ILC1s in the liver is currently unknown. However, it has 
been shown that these cells do have a unique capacity to generate 
immune memory responses against hapten and viral antigens 
(30). Unexpectedly, liver ILC1s could mediate recall responses 
in an antigen-specific manner. Thus far, however, neither the 
mechanisms nor the receptors involved in the specific recognition 
of the antigens are known and will require further investigation.
Thymic ILC1s
NKp46-expressing cells that reside in the thymus were first 
described as NK cells (11). However, a more recent understand-
ing of their phenotype suggests that they fit more closely with the 
description for ILC1. Thymic ILC1s differ from conventional NK 
cells as they express IL-7Rα and require the transcription factor 
Gata-3 for development (11) similar to other ILC1s (35) and 
should, therefore, be considered as members of the ILC1 subset 
(Figure 1B). Bone marrow-derived NK cells do not depend on 
Gata-3 during differentiation although it is important for them 
to produce IFN-γ during maturation. Thymic ILC1s display a 
phenotype that is intermediate between classical NK cells and 
ILC1s again adding to the debate around the classification of 
these cells. Similar to other ILC1s, thymic ILCs express low levels 
of Ly49 and high levels of IL-7Rα, CD11b, and CD69. They also 
express Eomes, a transcription factor normally characteristic of 
NK cells. Thymic ILC1s can develop in vitro and in vivo from the 
CD4−CD8− (DN1) subset of immature thymocytes, indicating 
that they do not arise from committed precursors in the bone 
marrow (42). To date, relatively little is known about the origins 
and contributions of thymic ILC1s to immune protection or 
homeostasis. Further work will be required to characterize these 
cells and establish their role in the thymus.
Intestinal ILC1s
At least three phenotypically distinct subsets of ILC1s can be 
found in the gut. In the lamina propria (LP) both NK cells and 
ILC1s (LP ILC1) have been described, while a third subset of 
ILC1s reside in the epithelium (ieILC1). LP ILC1s are character-
ized by high expression of IL-7Rα and the lack of Eomes while 
NK cells lack IL-7Rα and express Eomes (14). In humans, a 
subset of CD127+ IFN-γ-producing ILC1s have been identified 
in the gut and have been shown to be enriched in the intestine 
of Crohn’s disease patients (32). They are also enriched for 
CD69, but like ILC1s produce high level of IFN-γ and lack of 
Eomes expression. These cells do not express NKp46 or CD56 
but express CD161, a marker commonly expressed by the ILC3 
and ILC2 subsets.
An additional ILC1 subset has been reported in the gastroin-
testinal epithelia in both human and mice (31). These intraepi-
thelial ILC1s (ieILC1s) are characterized by the expression of 
lymphocyte markers, such as CD103 and CD160 (31). While 
human ieILC1s express NKp46, CD56, and NKp44, they also 
express Eomes similar to human LP ILC1s in contrast to murine 
ILC1 that do not express Eomes.
Salivary Gland ILC1s
ILC1s are found in the salivary gland and like those in some 
other sites express TRAIL, CD49a, CD103, and CD69 and express 
Eomes (34) (Table 1, Figure 1). Interestingly they develop inde-
pendent of the transcription factor Nfil3 that is similar to liver 
ILC1s, suggesting that salivary ILC1s may be distinct from NK 
cells that depend on Nfil3 for development (10). Recently, TGF-
β signaling has been implicated in the maintenance of salivary 
ILC1s (43). The lack of TGF-β signaling was associated with 
reduced numbers of ILC1 and impaired expression of CD49a, 
CD103, and CD69 in the salivary glands. By contrast, TGF-βR2 
deficiency had minimal impact on the phenotype of ILC1s found 
FiGURe 1 | (A) Phenotype of tissue-specific ILC1s and NK cells at steady-state. Characteristic markers of ILC1 in the thymus, liver, intestine, and salivary 
gland are depicted. On the left, the markers that are expressed by both ILC1s and NK cells are shown while on the right the marker that are only expressed 
by ILC1s are indicated. (B) Timeline highlighting important discoveries in the identification and characterization of NK cells and ILC1s. (1) Thornthwaite et al. 
(21). (2) Kiessling et al. (22). (3) Anderson (23). (4) Santoli et al. (24). (5) Karre et al. (25). (6) Takeda et al. (26). (7) Kim et al. (27). (8) Vosshenrich et al. (11). 
(9) Hayakawa et al. (28). (10) Huntington et al. (29). (11) Paust et al. (30). (12) Fuchs et al. (31). (13) Bernink et al. (32). (14) Seillet et al. (10). (15) Daussy et al. 
(33). (16) Cortez et al. (34). (17) Constantinides et al. (13). (18) Yagi et al. (35). (19) Gasteiger et al. (6). (20) Bernink et al. (36). (21) Bal et al. (37). (22) Ohne 
et al. (38).
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in the gut and the liver, suggesting that other factors guide their 
differentiation (43).
iLC1 PLASTiCiTY
Tools to investigate the distinct roles of ILC1s and NK cells are 
currently limited. At steady state, ILC1s and NK cells are distin-
guished based on the expression of surface markers (e.g., TRAIL, 
CD49a, CXCR6) and transcription factors (e.g., Eomes, PLZF). 
However, inflammation can modify these features complicating 
our ability to track bona fide ILC1s and NK cells. Surface mark-
ers, such as TRAIL or CD49a can be upregulated during MCMV 
infection or following exposure to cytokines, such as IL-2, IFN-γ, 
or IL-15 (20, 44, 45). During inflammation, cytokines can also 
divert ILC identity as has been shown for ILC2s and ILC3s, 
which can acquire a phenotype consistent with ILC1s. These so 
called “ILC1-like” cells that produce IFN-γ can arise from Rorγt+ 
NKp46-expressing ILC3s in the intestine following stimulation 
with cytokines, such as IL-12 and IL-18 (32, 46). LP ILC1s are 
also influenced by the microenvironment differentiating into 
Rorγt+ ILC3s when exposed to IL-23 and IL-1β. This process 
was enhanced in the presence of retinoic acid while IL-12 could 
reverse the transition (36). Similarly in the lung, IL-1β and IL-12 
can induce the conversion of ILC2s to ILC1-like cells (37, 38). 
These findings highlight that ILC are capable of rapid adaption 
to changes in environmental cues induced by pathogens or 
inflammation.
CONTRiBUTiON OF THe GROUP 1  
iLC TO PATHOGeN ReSPONSeS
Early resistance against intracellular bacteria has been attributed 
to the activation of phagocytic cells by NK cells through their 
capacity to produce IFN-γ (47, 48). However, the beneficial role 
of NK cells in these infections became contentious when more 
recent studies showed that depletion of NK1.1+ cells led to a 
reduction of bacterial load, a result that was not be concordant 
with the proposed positive role for NK cells. It would appear that 
during infection with Listeria monocytogenes, excessive IFN-γ 
produced by NK cells via activation through the costimulatory 
molecule CD27 impairs innate anti-bacterial defenses (49). 
This effect was not limited to Listeria infection (49, 50) as NK 
cell depletion also protected against lethal Escherichia coli (51) 
and Streptococcus pneumonia infection (52). An additional 
explanation for these paradoxical results, however, is that ILC1s 
and NK cells make differential contributions to defense against 
infection. These studies were conducted before the discovery of 
the ILC1s and have inevitably categorized all cells expressing 
NKp46 and NK1.1 and secrete IFN-γ and TNF-α as putative 
“NK cells.”
Re-investigation of the role of NKp46-expressing cells in the 
control of parasites, such as Toxoplasma gondii, revealed that 
ILC1s are indeed a major source of IFN-γ and TNF-α following 
oral infection (14). By contrast, NK cells or NKp46+ ILC3s 
appeared to have only minor contribution in these settings. 
However, whether ILC1s are solely responsible for the control of 
infection remains to be determined (14). In these experiments, 
the mice carried a germline deletion of T-bet resulting in a 
deficiency in their entire hematopoietic compartment and loss 
of IFN-γ expression in ILC1s, NK and NKp46+ ILC3s. These 
experiments, therefore, do not delineate the role of T-bet in 
the various different immune populations that might control 
infection. Although adoptive transfer of ILC1 into Rag2−/−γC−/− 
mice was found to reduce the Toxoplasma pathogen load, it 
only partially restored the recruitment of monocytes to a 
level similar to those observed in T-bet−/− mice. Similarly, in 
response to Clostridium difficile, ILC1s have been shown to 
be the major contributor to IFN-γ production during acute 
infection rather than NK cells (53). Early protection against 
C. difficile was mediated by T-bet-expressing ILC1s in a IFN-
γ-dependent manner.
These results collectively imply that the enhanced capacity of 
ILC1s to produce IFN-γ outstrips that of NK cells during enteric 
infection such that ILC1s may be the main drivers of immune 
protection. In addition, the potential plasticity of ILCs allowing 
the polarization of ILC3s toward an ILC1-like phenotype may 
further favor efficient IFN-γ production by ILC1s. However, due 
to the paucity of models that allow targeted deletion of ILC1 alone, 
it remains complicated to formally demonstrate the specific and 
non-redundant roles of ILC1. Further characterization of the 
ILC1 populations and identification of the transcription factors 
regulating their development may shed light on new approaches 
for in vivo models with which ILC1s functions can be specifically 
assessed.
CONTRiBUTiON OF THe GROUP 1  
iLC iN CANCeR AND iNFLAMMATiON
Tumor Rejection
Natural killer cells are able to distinguish transformed cells from 
normal healthy cells, in part by their reduced expression of major 
histocompatibility complex class I (MHC-I) molecules, the 
founding feature of the “missing-self ” hypothesis. Both in vivo 
and in vitro experiments in humans and mice have demonstrated 
that MHC-I deficient tumor cells are more sensitive to NK cell-
mediated cytolysis (25). However, the mechanisms regulating the 
activation and inhibition of NK cells are more complex than the 
original “missing-self ” hypothesis (54). Studies have shown that 
cytotoxicity of NK cells against transformed cells is governed 
by both cytokines and activating and inhibitory receptors. To 
suppress tumors, NK cells can cause direct cell target death by 
granule-mediated lysis, receptor mediated cytotoxicity (Fas/FasL 
or TRAIL death pathway) (55, 56), or antibody-dependent cell 
cytotoxicity (ADCC) (57). Besides direct killing of tumor cells, 
NK cells can secrete TNF-α and IFN-γ to drive the Th1 polariza-
tion in the tumor microenvironment to further strengthen adap-
tive cytotoxic responses to tumor cells (58).
In contrast to NK cell activation, ILC1s have not been reported 
to exhibit crosstalk with other cells through activating and inhibi-
tory signals. Instead, they are activated by cytokines, such as IL-12, 
IL-15, and IL-18, which are also able to drive NK cell activation 
(31). Following activation, ILC1s can also produce TNF-α and 
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IFN-γ. It has been proposed that ILC1s should be classified as 
innate “helper-like” cells distinguishing them from NK cells that 
would represent cytotoxic ILCs (14), however, it has been shown 
that liver ILC1s are also able to recognize and kill target cells 
albeit perhaps less efficiently than NK cells (30, 59). This killing 
capacity would enable tissue-resident ILC1s to have potentially 
important roles in controlling transformed cells at an early devel-
opment stage prior to their dissemination throughout the body. 
Recently, it was reported that early stage cell transformation can 
induce a local tissue-resident lymphocyte response accompanied 
by expression of Granzyme B and potentially cytolytic activity 
toward the transformed cells (60). These tumor-associated ILC1s 
appear to be transcriptionally distinct from, but functionally 
related to, conventional NK cells and differ from ILC1s found 
at steady state. These cells, though, were dependent on IL-15 but 
did not require Nfil3 for development similar to ILC1s. These 
data suggest that tumor-associated ILC1s are developmentally 
distinct from NK cells as it has been shown for liver (10) and 
salivary gland ILC1s (34). However, it has been also shown that 
Nfil3 is not required for mature NK cell homeostasis and that 
Nfil3-deficient mice are able to generate and maintain NK cell 
memory in response to MCMV infection (61).
Transplantation and Graft-versus-Host 
Disease
A common clinical situation where both acute and chronic 
inflammation occurs is transplantation. Either solid organ 
or hematopoietic cell transplantation (HCT), including bone 
marrow transplantation (BMT), can lead to both host and 
donor immune reactions, mainly attributed to mismatched 
MHC molecules from the host and the donor. These immune 
reactions involve inflammation of multiple organs and are 
categorized into host-versus-graft disease (HVGD) and graft-
versus-host disease (GVHD) reflecting the origins of target 
and activated immune cells. When host immune cells react 
against donor cells, elevation in serum cytokine levels and 
multi-organ inflammation gives rise to HVGD and typically 
graft failure results. Conversely, GVHD is the disease associ-
ated with systemic inflammation caused by activation of donor 
immune cells that damage the host tissue, a very common 
clinical complication after HCT. The alloreactivity from donor 
NK cells against recipient cells can cause selective cytolysis 
and damage to host cells and tissues, suggesting that it may 
be entirely deleterious but paradoxically this effect sets the 
scene for a potent graft-versus-leukemia (GVL) effect that 
effectively removes leukemic cells leading to positive outcomes. 
Alloreactive NK cells reduce GVHD by eliminating recipient 
antigen-presenting cells that drive immune cell activation 
(62). In a murine model of MHC-matched allogeneic BMT, 
the infusion of Ly-49 (a member of the inhibitory receptor 
family) mismatched NK cells contributed significantly to the 
anti-tumor effect while preventing GVHD (63). The infusion of 
pre-activated NK cells with a combination of cytokines, such 
as IL-12/15/18, strongly suppressed acute GVHD (64). These 
NK cells were found to maintain their expression of Eomes 
and T-bet in vivo which they exhibited prior to transfer which 
suggests that the key effectors in this setting are NK cells and 
not ILC1, which have a different profile (64).
Interestingly, mice reconstituted with cells that lack NKp46 
expression had greatly exacerbated GVHD and increased 
 mortality due to increased commensal bacteria infection (65). 
As both NK cells and ILC1s express NKp46, this clinical outcome 
may reflect the involvement of both cell types but it is not clear 
how NK cells and ILC1s individually contribute to the disease 
progression. To date, only a single study has reported a protective 
role for ILCs in GVHD (66). In this study, patients that did not 
develop acute GVHD had increased proportions of skin-homing 
ILC1s, NCR− ILC3s and gut-homing ILC2s, suggesting that ILCs 
can indeed provide protection against the development of GVHD 
(66). It was observed that following transplantation, patients that 
developed more severe GVHD had fewer circulating ILC1s when 
compared with healthy controls. Mobilization of ILC1s follow-
ing treatment was associated with elevated expression of the 
early activation marker CD69, and the tissue homing markers 
CLA and CCR10 which correlated with less severe progression 
of GVHD. Nevertheless, the recovery of ILCs following condi-
tioning radio-therapy and chemotherapy was slow compared 
with other immune cell types and the reconstituting ILCs were 
derived from the donor. It appears that both ILC1s and NK cells 
from donors can exert protective roles to restrict the progression 
of GVHD while simultaneously contributing to the GVL effect. 
This suggests that balancing the ratios of donor and host ILC1s/
NK cells through conditioning prior to BMT may be important 
for high engraftment and robust GVL effects and substantially 
negating the risk of GVHD.
CONCLUSiON
With the identification of different ILC1 subsets in virtually 
every tissue in the body, it has become clear that these cells 
do not express a unique characteristic marker that singularly 
defines this subset. Some ILC1s, such as liver-resident ILCs, have 
a relatively well-defined phenotype, location, and origin, and 
this is clearly distinct from NK cells. In other tissues, such as 
the thymus or salivary glands, ILC1s appear to share a number 
of features with NK cells (Table  1, Figure  1). This includes 
the expression of Eomes and CD49b. Thus, whether all ILC1 
subsets represent one distinct lineage with the same progenitor 
and blueprint for transcriptional regulation is not clear. It seems 
unlikely. Liver and salivary gland ILC1s do not require NFIL3 
for their development while ILC1s in the gut it is essential (10, 
34, 67). More intriguingly, ILC1s exhibit a differential need for 
IL-15 depending tissue they reside (31). Nevertheless, ILC1s 
appear to be very adaptable and their phenotype strongly reflects 
their varied microenvironments in which they exist. They appear 
to develop from precusors in the fetal liver, bone marrow, or 
thymus, but can also, somewhat surprisingly, transdifferentiate 
from other ILC lineages, including ILC2s and ILC3s. Thus, 
in order to understand the contribution of ILC1 to immune 
protection, further work will be required to better characterize 
the origin, transcriptional regulation and perhaps most impor-
tantly how microenvironmental factors drive their development 
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and plasticity. This will depend significantly on the generation 
of novel models in which ILC1s can be specifically deleted 
without affecting the NK cell compartment and allow detailed 
understanding of the precise role of ILC1s during infections 
and inflammatory diseases.
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